Oncology Based In-vivo CRO Market Report

Oncology Based In-vivo CRO Market Analysis By Indication (Blood cancer, Solid tumor), By Model (Syngeneic model, Patient Derived Xenograft (PDX), Xenograft), By Region, And Segment Forecasts, 2014 - 2025

Published: May 2017  |  64 Pages  |  Format: PDF  |  Report ID: GVR-1-68038-859-6

Industry Insights

The global oncology based in-vivo CRO market size was valued at USD 725.0 million in 2016 and is expected to grow at a CAGR of over 8.0% over the forecast period. Immunodeficient mice based models are commonly utilized to conduct oncology research across the globe. Factors responsible for the steady growth of this industry are the rising cases of cancer, availability of government funding for research purposes, and growing expertise for cancer by CROs.

As of 2016, numerous players, both large and small scale are competent to perform preclinical studies for establishing the toxicology and therapeutic effect for upcoming cancer drugs. Furthermore, owing to innovation in the field of genetic, efforts towards studying the oncogene and growing concern of pharmaceutical companies towards optimizing their research findings are certain vital impact rendering drivers of the market.

U.S. oncology based in-vivo CRO market, by indication, 2014 - 2025 (USD Million)

U.S. oncology based in-vivo CRO market

For instance, according to an article published in the International Weekly Journal of Science in May 2012, the adoption of therapeutic molecules into clinical research for cancer has been relatively low owing to large failure rates by pharmaceutical companies. The reason for failure were many, which also include the lack of expertise and level of quality for preclinical studies. Hence, opting for expertise through outsourcing to competent CRO’s is anticipated to drive the industry over the forecast period.

The aforementioned drawback also made the government and other research organizations understand the tilt towards higher spending in clinical studies over preclinical, which eventually led to higher failure rate. This in turn has been promoting pharmaceutical companies to reserve higher funds for preclinical research activities as of 2016, thereby promoting market growth.

Indication Insights

The oncology based in-vivo CRO market has been analyzed on the basis of blood cancer, solid tumors and other indications. Solid tumors dominate the segment as of 2016 with over 40.0% of the market share.

The factors responsible for higher research in the field of solid tumors includes the presence of over 800 new molecules that are in pipeline by large pharmaceutical companies, availability of grants from institutes such as the NIH and NCI, and existing gap between demand and supply of therapeutic treatments for solid cancer.

According to statistics provided by the government bodies across the world, besides infectious diseases’ vaccine development, oncology is one of the most researched indications. According to the Wilmot Cancer Institute, as of 2015, rigorous studies in the preclinical phase for a new class of drug called tyrosine kinase inhibitors is being conducted.

Solid tumors are cancer occurring within organs, muscles or bones. These are generally addressed as carcinomas, and sarcomas. The increasing incidence of cancer across the globe and growing interest of world agencies such as the WHO in analyzing their prevalence, causative agents and treatment options is boosting the R&D. For instance, BioInvent, a Swedish CRO is currently performing multiple preclinical oncology research in collaboration with players such as Bayer Healthcare, Daiichi Sankyo, and Servier.

Model Insights

Based on the type of model employed to conduct research, the global market of oncology based in-vivo CRO is segmented into syngeneic, xenograft, and Patient Derived Xenograft (PDX) models. As of 2016, PDX forms the largest as well as the fastest growing segment over the forecast period. Prior to PDX, xenograft models held a substantial market share owing to the benefits of incorporating the targeted tumor cells within the animal models.

The PDX models allow for higher correlation between the researched outcome and final therapeutic impacts observed within clinical trial participants, and are thus becoming the choice of model among researchers. This segment is expected to grow at a CAGR of over 8.0%.

PDX mice models are the most commonly used approaches for validating the results obtained in the in-vivo studies of cancer drug candidates. The preclinical studies for cancer are driven by the personalized approach, which is the current trending therapy. In 2014, GuizhongLui of Crown Bioscience, Inc. published a paper stating the advantages of using a Patient Derived Xenograft (PDX) model in mice.

According to our analysis, these xenografts reduce both the time taken to conduct studies as well as the attached costs leading to faster and precise decisions for the drug development. Furthermore, a combination of these models when applied together with bioinformatics aids in the selection of appropriate human groups, which in turn lead to non-erroneous selection of candidates for the clinical trials.

There are various organizations across the globe that are dedicated to studying oncology in animal models. For instance, The University of California, San Francisco’s Helen Diller Family Comprehensive Cancer Center performs preclinical trials in tumor bearing animals. The organization on a subscription basis share their knowledge, expertise, and provide training to other institutes.

Global oncology based in-vivo CRO market, by model, 2016 (%)

Global oncology based in-vivo CRO market

Regional Insights

Regionally, the U.S. market is most dominant, thereby making North America the largest revenue generator for the oncology based in-vivo CRO market. Presence of ample funding in this region impacted the research activities positively. Moreover, major pharmaceutical and life sciences companies which are involved in drug development are present in this region. With well-planned regulatory and funding policies, the market in this region held remunerative shares.

The U.S. has the highest per capita healthcare spending and availability of funding and grants from government organizations. For instance, according to data provided by the NIH, in 2012 about 47.0% of the total funding allotted for research was spent within the preclinical analysis space.

On the other hand, Asia Pacific is anticipated to witness fastest growth over the forecast period.

Factors identified to support this growth include the rapidly evolving healthcare infrastructure and inclusion of research activities by medium as well as small scale players. Furthermore, the augmenting figure of patients within the region coupled with flexible regulatory guidelines are expected to promote the region as key destination to existing CROs.

In October 2014, the Australian CRO Novotech started a new office in China, its ninth office in Asia. Novotech, as a company, has expanded in many developing nations owing to the request by its U.S and EU clients. In addition, in February 2014, the Charles River Laboratories also expressed their interest to enter into the Chinese market owing to the large population base and limited players.

Competitive Insights

Key players profiled for the oncology based in-vivo CRO market include Crown Bioscience, Charles River Laboratory, ICON Plc., Eurofins Scientific, Taconic Biosciences, Covance, EVOTEC, The Jackson Laboratory, and Wuxi AppTec. Other players operating in this space are MI Bioresearch, Inc., Living Tumor Laboratory, Champion Oncology, Inc. and Xentech.

Owing to the augmenting rate at which outsourcing of activities is growing within the healthcare industry, entry of various new players coupled with collaborative efforts by existing players is expected to be witnessed over the forecast period. For instance, EVOTEC has formed collaboration with Inserm and various other research organizations across Europe.

Similarly, in March 2015, Cellaria Biosciences and Taconic Biosciences entered into a collaboration to promote development and higher use of PDX xenograft models. Other strategic plans are development of new databases and PDX based models to serve the current unmet needs.

For instance, in February 2017, Crown Biosciences announced the launch of their advanced digital platform for their oncology database “OncoExpress”. The platform was previously launched in mid-2015, but the current version is incorporated with enhanced search options and analytical capabilities, thereby driving innovation within oncology research.

Report Scope

Attribute

Details

Base year for estimation

2016

Actual estimates/Historic data

2014 - 2016

Forecast period

2017 - 2025

Market representation

Revenue in USD Million & CAGR from 2017 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America & MEA

Country scope

U.S., Canada, UK, Germany, Japan, China, Brazil, Argentina, South Africa, Saudi Arabia

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

15% free customization scope(equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the oncology based in-vivo CRO market on the basis of indication, and region:

  • Indication Outlook (Revenue, USD Million, 2014 - 2025)

    • Blood cancer

    • Solid tumors

      • Syngeneic model

      • Patient Derived Xenograft (PDX)

      • Xenograft

    • Other

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • UK

      • Germany

    • Asia Pacific

      • Japan

      • China

    • Latin America

      • Brazil

      • Argentina

    • Middle East and Africa (MEA)

      • South Africa

      • Saudi Arabia

Key questions answered by the report
Request for Customization

Choose License Type:

Single User - $3,450
Multi User - $6,450
Enterprise User - $8,450

Special Pricing & Discounts

Avail customized purchase options to meet your research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Custom research service

    Custom research service

    Speak to the report author to design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service excellence represented in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • BOA